Max Crispin

19.2k total citations · 3 hit papers
157 papers, 9.1k citations indexed

About

Max Crispin is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Max Crispin has authored 157 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Molecular Biology, 64 papers in Radiology, Nuclear Medicine and Imaging and 53 papers in Immunology. Recurrent topics in Max Crispin's work include Glycosylation and Glycoproteins Research (81 papers), Monoclonal and Polyclonal Antibodies Research (64 papers) and HIV Research and Treatment (50 papers). Max Crispin is often cited by papers focused on Glycosylation and Glycoproteins Research (81 papers), Monoclonal and Polyclonal Antibodies Research (64 papers) and HIV Research and Treatment (50 papers). Max Crispin collaborates with scholars based in United Kingdom, United States and Netherlands. Max Crispin's co-authors include Yasunori Watanabe, Joel D. Allen, David J. Harvey, Thomas A. Bowden, Raymond A. Dwek, Jason S. McLellan, Christopher N. Scanlan, Ian A. Wilson, Daniel Wrapp and Katie J. Doores and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Max Crispin

150 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Site-specific glycan analysis of the SARS-CoV-2 spike

2020 1.0k citations Yasunori Watanabe, Joel D. Allen et al. Science profile →
Molecular Architecture of the SARS-CoV-2 Virus

2020 703 citations Max Crispin et al. profile →
Exploitation of glycosylation in enveloped virus pathobiology

2019 348 citations Yasunori Watanabe, Thomas A. Bowden et al. profile →

Peers

Countries citing papers authored by Max Crispin

Since Specialization

Citations

This map shows the geographic impact of Max Crispin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Crispin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Crispin more than expected).

Fields of papers citing papers by Max Crispin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Crispin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Crispin. The network helps show where Max Crispin may publish in the future.

Co-authorship network of co-authors of Max Crispin

This figure shows the co-authorship network connecting the top 25 collaborators of Max Crispin. A scholar is included among the top collaborators of Max Crispin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Crispin. Max Crispin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Design and Immunogenicity of an HIV-1 Clade C Pediatric Envelope Glycoprotein Stabilized by Multiple Platforms 2025 ·Vaccines ·Sanjeev Kumar, Iván del Moral-Sánchez, (unknown), Maddy L. Newby, Joel D. Allen, Tom P. L. Bijl, (unknown), (unknown), Rakesh Lodha, Eric A. Ortlund, Max Crispin, Anamika Patel, (unknown), Kalpana Luthra	1
2	The origin, diagnosis, and prognosis of oligomannose-type diffuse large B-cell lymphoma 2025 ·Blood ·(unknown), Maddy L. Newby, Joel D. Allen, (unknown), Giorgia Chiodin, Patrick J. Duriez, John Butler, Katy J. McCann, David W. Scott, Ryan D. Morin, Kostiantyn Dreval, Andrew Davies, (unknown), Max Crispin, Francesco Forconi	0
3	From sequence to scaffold: Computational design of protein nanoparticle vaccines from AlphaFold2-predicted building blocks 2025 ·Proceedings of the National Academy of Sciences ·(unknown), (unknown), Annie Dosey, Joel D. Allen, Rebecca A. Gillespie, (unknown), Elizabeth M. Leaf, Max Crispin, Cole A. DeForest, Masaru Kanekiyo, Neil P. King	0
4	Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein 2024 ·npj Vaccines ·Young Chan Kim, Yasunori Watanabe, (unknown), Xiyong Song, (unknown), (unknown), Sasha R. Azar, Shannan L. Rossi, Carla Claser, Beate M. Kümmerer, Max Crispin, Thomas A. Bowden, Juha T. Huiskonen, Arturo Reyes‐Sandoval	3
5	Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity 2024 ·Glycobiology ·(unknown), Tommy Tong, Emma T. Crooks, Keiko Osawa, (unknown), (unknown), Joel D. Allen, Max Crispin, James Μ. Binley	0
6	Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies 2023 ·Cell Reports ·Hailee R. Perrett, Philip J. M. Brouwer, Jonathan Hurtado, Maddy L. Newby, Lin Liu, Helena Müller-Kräuter, (unknown), Judith A. Burger, Joey H. Bouhuijs, (unknown), Terrence Messmer, John S. Schieffelin, Aleksandar Antanasijevic, Geert‐Jan Boons, Thomas Strecker, Max Crispin, Rogier W. Sanders, Bryan Briney, Andrew B. Ward	14
7	High thermostability improves neutralizing antibody responses induced by native-like HIV-1 envelope trimers 2022 ·npj Vaccines ·Iván del Moral-Sánchez, Rebecca A. Russell, Edith E. Schermer, Christopher A. Cottrell, Joel D. Allen, Alba Torrents de la Peña, Celia C. LaBranche, Sanjeev Kumar, Max Crispin, Andrew B. Ward, David C. Montefiori, Quentin J. Sattentau, Kwinten Sliepen, Rogier W. Sanders	12
8	Uncovering cryptic pockets in the SARS-CoV-2 spike glycoprotein 2022 ·Structure ·(unknown), Firdaus Samsudin, (unknown), (unknown), Jan K. Marzinek, (unknown), Conrado Pedebos, Nikhil Kumar Tulsian, Jim Warwicker, Paul A. MacAry, Max Crispin, Syma Khalid, Ganesh S. Anand, Peter J. Bond	25
9	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates 2021 ·Science Translational Medicine ·Lars Hangartner, (unknown), Eva G. Rakasz, Rebecca Nedellec, Nathanaël Hozé, (unknown), Maurício A. Martins, Gemma E. Seabright, Joel D. Allen, Andrea M. Weiler, Thomas C. Friedrich, Roland R. Regoes, Max Crispin, Dennis R. Burton	26
10	Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints 2021 ·Analytical Chemistry ·(unknown), Joel D. Allen, Maddy L. Newby, Max Crispin	13
11	A cross-neutralizing antibody between HIV-1 and influenza virus 2021 ·PLoS Pathogens ·Chang‐Chun D. Lee, Yasunori Watanabe, Nicholas C. Wu, Julianna Han, Sonu Kumar, Tossapol Pholcharee, Gemma E. Seabright, Joel D. Allen, Chih-Wei Lin, Ji‐Rong Yang, Ming‐Tsan Liu, Chung‐Yi Wu, Andrew B. Ward, Max Crispin, Ian A. Wilson	23
12	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens 2021 ·PLoS Pathogens ·Emma T. Crooks, (unknown), (unknown), E. Duggan, Jinsong Zhang, Kshitij Wagh, Huihui Mou, Joel D. Allen, (unknown), Keiko Osawa, Bette Korber, Yaroslav Tsybovsky, Evan M. Cale, John P. Nolan, Max Crispin, Laurent Verkoczy, James Μ. Binley	8
13	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation 2020 ·Nature Communications ·Yasunori Watanabe, Zachary T. Berndsen, Jayna Raghwani, Gemma E. Seabright, Joel D. Allen, Oliver G. Pybus, Jason S. McLellan, Ian A. Wilson, Thomas A. Bowden, Andrew B. Ward, Max Crispin	240
14	Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers 2018 ·Science ·Talar Tokatlian, Benjamin J. Read, Christopher A. Jones, Daniel W. Kulp, Sergey Menis, Jason Y.H. Chang, Jon M. Steichen, Sudha Kumari, Joel D. Allen, Eric L. Dane, Alessia Liguori, Maya Sangesland, Daniel Lingwood, Max Crispin, William R. Schief, Darrell J. Irvine	212
15	HIV-1 vaccine design through minimizing envelope metastability 2018 ·Science Advances ·Linling He, Sonu Kumar, Joel D. Allen, Deli Huang, Xiaohe Lin, Colin Mann, Karen L. Saye-Francisco, Jeffrey Copps, Anita Sarkar, (unknown), Gabriel Ozorowski, Devin Sok, Max Crispin, Andrew B. Ward, David Nemazee, Dennis R. Burton, Ian A. Wilson, Jiang Zhu	60
16	Signature of Antibody Domain Exchange by Native Mass Spectrometry and Collision-Induced Unfolding 2018 ·Analytical Chemistry ·Yasunori Watanabe, Snežana Vasiljević, Joel D. Allen, Gemma E. Seabright, Helen M. E. Duyvesteyn, Katie J. Doores, Max Crispin, Weston B. Struwe	31
17	Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy 2017 ·Molecular Cancer Therapeutics ·Sofia Järnum, Anna Runström, Robert Bockermann, Lena Winstedt, Max Crispin, Christian Kjellman	9
18	Identification of Lewis and Blood Group Carbohydrate Epitopes by Ion Mobility-Tandem-Mass Spectrometry Fingerprinting 2017 ·Analytical Chemistry ·Johanna Hofmann, (unknown), Max Crispin, David J. Harvey, Kevin Pagel, Weston B. Struwe	60
19	Emerging Principles for the Therapeutic Exploitation of Glycosylation 2014 ·Science ·Martin Dalziel, Max Crispin, Christopher N. Scanlan, Nicole Zitzmann, Raymond A. Dwek	369
20	Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens 2010 ·Proceedings of the National Academy of Sciences ·Katie J. Doores, Camille Bonomelli, David J. Harvey, Snežana Vasiljević, Raymond A. Dwek, Dennis R. Burton, Max Crispin, Christopher N. Scanlan	263

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact